List of Xipere drug patents

Xipere is owned by Bausch And Lomb Inc.

Xipere contains Triamcinolone Acetonide.

Xipere has a total of 3 drug patents out of which 0 drug patents have expired.

Xipere was authorised for market use on 22 October, 2021.

Xipere is available in suspension;injection dosage forms.

Xipere can be used as treatment of macular edema associated with uveitis.

The generics of Xipere are possible to be released after 02 May, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8636713 BAUSCH AND LOMB INC Methods and devices for drug delivery to ocular tissue using microneedle
May, 2027

(4 years from now)

US9636332 BAUSCH AND LOMB INC Methods and devices for the treatment of ocular diseases in human subjects
Nov, 2033

(10 years from now)

US9937075 BAUSCH AND LOMB INC Apparatus and methods for ocular injection
May, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 22, 2024

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 22 October, 2021

Treatment: Treatment of macular edema associated with uveitis

Dosage: SUSPENSION;INJECTION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in